NYSE:GKOS - Glaukos Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$60.45 +0.51 (+0.85 %)
(As of 09/20/2018 04:00 PM ET)
Previous Close$59.94
Today's Range$59.77 - $60.84
52-Week Range$23.08 - $70.91
Volume313,500 shs
Average Volume588,024 shs
Market Capitalization$2.18 billion
P/E Ratio1,246.80
Dividend YieldN/A
Glaukos logoGlaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. The company markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation has a collaboration agreement with D. Western Therapeutics Institute for the development of novel intraocular products for the treatment of glaucoma. The company was founded in 1998 and is headquartered in San Clemente, California.

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments


Debt-to-Equity RatioN/A
Current Ratio7.63
Quick Ratio6.95


Trailing P/E Ratio1,246.80
Forward P/E Ratio-109.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$159.25 million
Price / Sales13.25
Cash Flow$0.1517 per share
Price / Cash398.45
Book Value$4.00 per share
Price / Book15.11


EPS (Most Recent Fiscal Year)N/A
Net Income$-90,000.00
Net Margins-3.49%
Return on Equity-4.11%
Return on Assets-3.54%


Outstanding Shares34,910,000
Market Cap$2.18 billion

Glaukos (NYSE:GKOS) Frequently Asked Questions

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) issued its earnings results on Thursday, August, 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical instruments supplier earned $43.16 million during the quarter, compared to analysts' expectations of $40.51 million. Glaukos had a negative return on equity of 4.11% and a negative net margin of 3.49%. The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm posted ($0.10) earnings per share. View Glaukos' Earnings History.

When is Glaukos' next earnings date?

Glaukos is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Glaukos.

What price target have analysts set for GKOS?

10 Wall Street analysts have issued 12-month price targets for Glaukos' stock. Their predictions range from $35.00 to $75.00. On average, they anticipate Glaukos' share price to reach $59.7778 in the next year. This suggests that the stock has a possible downside of 1.1%. View Analyst Price Targets for Glaukos.

What is the consensus analysts' recommendation for Glaukos?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos.

What are Wall Street analysts saying about Glaukos stock?

Here are some recent quotes from research analysts about Glaukos stock:
  • 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (8/7/2018)
  • 2. Cantor Fitzgerald analysts commented, "Executing Well in a Slightly Adverse Environment. Glaukos reported 37% YoY revenue growth, falling a little short of the 40%+ growth since the launch of iStent slightly more than four years ago (88% of the sales were recorded in the U.S.). The company reported to be on track to have trained >3,000 surgeons by YE17. Glaukos operated in an environment, which was affected by a number of factors: 1: the slow institution of higher reimbursement (challenging during implementation, but favorable afterwards) by commercial payors (20% of total); 2: hurricane-caused delays in surgery ($1 million impact in 3Q17); 3: a negative impact by a single Medicare operator (lowering surgeon’s fees) and by continued sampling and perhaps early sales by competitor Alcon (wholly owned by NVS [Not Covered]). Long term, we believe Glaukos’ iStent has demonstrated significant long-term benefit and cost efficiency to maintain a commercial and competitive advantage. The company remained cautious about 2018, due to the expanded launch by Alcon, a second competitor potentially arriving to the market by 2H18 (Hydrus by Ivantis [private]) and the relatively modest contribution by iStent Inject (PMA to be submitted by YE17). 2018 guidance will be introduced in January at the 4Q17 earnings call." (11/7/2017)

Who are some of Glaukos' key competitors?

Who are Glaukos' key executives?

Glaukos' management team includes the folowing people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 57)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 42)
  • Mr. Chris M. Calcaterra, COO & Chief Commercial Officer (Age 58)
  • Mr. Richard L. Harrison, Advisor (Age 61)
  • Dr. Mory Gharib Ph.D., Co-Founder

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Has Glaukos been receiving favorable news coverage?

Media stories about GKOS stock have trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Glaukos earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Glaukos.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by many different of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (13.95%), BlackRock Inc. (6.92%), Gilder Gagnon Howe & Co. LLC (3.71%), Baillie Gifford & Co. (3.47%), Waddell & Reed Financial Inc. (3.20%) and FMR LLC (3.03%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.

Which major investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Meritech Capital Associates III L.L.C., Janus Henderson Group PLC, C WorldWide Group Holding A S, Bank of America Corp DE, GSA Capital Partners LLP, Granite Investment Partners LLC and Peregrine Capital Management LLC. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Orbimed Advisors Llc and Thomas William Burns. View Insider Buying and Selling for Glaukos.

Which major investors are buying Glaukos stock?

GKOS stock was bought by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., BlackRock Inc., Rhenman & Partners Asset Management AB, FMR LLC, Renaissance Technologies LLC, Baillie Gifford & Co., Jennison Associates LLC and Fred Alger Management Inc.. View Insider Buying and Selling for Glaukos.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $60.45.

How big of a company is Glaukos?

Glaukos has a market capitalization of $2.18 billion and generates $159.25 million in revenue each year. Glaukos employs 387 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]

MarketBeat Community Rating for Glaukos (NYSE GKOS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  486
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel